Built by Grok 4.6 High

Reports Wednesday, October 21, 2026. Prepared Thursday, September 24, 2026. This is the Q3 FY2026 print (quarter ending September 30). It has not been reported. Release at 6:00 a.m. ET, call at 8:00 a.m. ET. Last reported quarter is Q2 FY2026, released the morning of July 21, 2026. Danaher is a calendar-year company. The homepage calendar labels this date 2026Q4 and October 20; that label is the announcement-month quarter and the date is one day early. This page is 2026Q3.

DHR | Earnings Preview

Danaher reports Q3 on Wednesday, October 21, with the July 21 guide still the only operating word. On that call the company printed sales of $6,265 million, core growth of 3.0%, and adjusted diluted EPS of $1.94, then cut the top of FY2026 core growth from 6% to 4% and raised FY adjusted EPS to $8.45–$8.60. The quarter now in front of us was guided, on the same call, to core growth of 2%–3%, about 5% excluding respiratory, and an adjusted operating margin of about 26.5%. The August 3 CEO release said that stack is unchanged. Nothing since has replaced it.

Growth trajectory. Full-year core went from -10.0% in 2023 to -1.5% in 2024 to +2.0% in 2025. The live 3–4% guide is another step up from +2%, and a smaller step than the 3–6% range that opened the year. Quarterly headline core reaccelerated from 0.5% in Q1 to 3.0% in Q2, +250 bps in the YoY rate, and +150 bps versus Q2 2025's 1.5%. That 3.0% is not faster than the 3.0% being lapped in Q3 2025. The guide midpoint of 2.5% is −50 bps versus that quarter. The underlying line is going the other way versus the quarter being lapped. The supplement puts Q3 2025 ex-respiratory core at +2.5%, and the Q3 guide of about 5% is +250 bps versus that rate. The segments did not move together. Life Sciences core went from -2.5% to 5.5%, +800 bps. Biotechnology core went from 6.0% to 2.5%, −350 bps, after six quarters at 6–8%. Diagnostics core was unchanged at 2.0%.

Margins are compressing where respiratory mix hits, and expanding where Life Sciences came back. Gross margin fell to 57.6% from 59.3%, −170 bps. Adjusted operating margin fell to 27.1% from 27.3%, −20 bps, and that 27.1% still beat the prior 26.5% bogey by 60 bps. A guided 26.5% in Q3 versus Q3 2025's 27.9% is −140 bps if they only meet it. Adjusted EPS growth of +7.8% in Q2 ($1.94 versus $1.80) is slower than Q3 2025's +10.5%. The FY midpoint of $8.525 is about +9.3% versus FY2025 $7.80, and almost all of the remaining growth is in the Q4 Street number, not in Q3.

What consensus is underwriting. FMP for the unreported October 21 row is EPS $1.91 and revenue $6,554 million. Versus Q3 2025 that is +1.1% on EPS against $1.89 and +8.3% on revenue against $6,053 million. Core excludes acquisitions and currency. A 2.5% core midpoint plus the guided −1.0% FX impact is only about +1.5% before M&A, roughly $6.14 billion on the Q3 2025 base. The Street's $6,554 million sits about $410 million above that bridge. That gap is the first full quarter of Masimo, which closed June 10 and is excluded from core. Do not read +8.3% as the Street sitting above the 2–3% core guide. FY EPS of $8.51 (15 analysts) is inside $8.45–$8.60, about 2 cents under the $8.525 midpoint and 6 cents above the floor. Internal models, Visible Alpha, and Bloomberg were not available.

What to watch on October 21

• Core inside 2–3%, and whether ex-respiratory actually steps to about 5%. The headline can "beat" at 3% and still be slower than Q2 and no faster than the quarter being lapped. The acceleration they are selling is the ex-respiratory line.
• Respiratory at about $325 million. That is the entire ~250 bp headwind. A lighter season is how Q1's headline core missed. A stronger season lifts core and mixes the margin the other way. Q3 2025 respiratory was a small tailwind, which is why this compare is the worst of the year.
• The 26.5% margin after a 170 bp gross-margin decline. They have beaten the margin bogey in six of the last seven scored quarters, but the last beat was only +60 bps. The sandbag is thinner. Meeting 26.5% exactly would be a guided year-over-year decline, not a productivity story.
• Biotechnology mid-single digit versus mid-teens orders. A little north of $100 million of chromatography-resin shipments left Q2 and Q3 and is not in the Q4 plan. Orders are the bullish sentence management keeps repeating. The published guide does not assume the street believes it.
• Masimo in the dollar, not in core. The $6,554 million bar is won or lost on the first full quarter, not on whether core is 2% or 3%. Diagnostics adjusted profit barely grew in Q2 while reported sales did. If the full quarter arrives as revenue without adjusted profit, EPS is the line that breaks.
• Tariffs are not in the P&L and are about to enter the definition of core. The Q2 10-Q says 2025 and first-half 2026 tariffs, and related refunds, were not material. Beginning with the Q3 10-Q, Danaher intends to exclude from core sales any tariff refunds from prior periods that are returned, or expected to be returned, to customers. Worth a footnote on the bridge. Not, on the company's words, a reason to move 2–3%.
• The CEO changes before the call, and the guide does not. Julie Sawyer Montgomery becomes President and CEO on October 1. The October 21 call is twenty days into her tenure. Q3 execution is still Blair's quarter. Blair sold 58,255 trust shares on August 21. The Form 4 does not flag a 10b5-1 plan.

No close life-science tools peer reports before Danaher. Johnson & Johnson on October 13 is hospital and device tone, not Cytiva or Cepheid. Intuitive Surgical lists a call after the close on October 20. Quest, the lab read-through, reports the morning after, on October 22. A cautious bioprocessing comment from Danaher hits the tape before Thermo Fisher, Revvity, Waters, and IQVIA.

Danaher does not guide quarterly revenue dollars or quarterly adjusted EPS. The commitments that will be scored on October 21 are core growth, the ex-respiratory rate, respiratory dollars, and the margin point. Classification: conservative on those floors. The 4% top of the FY core range is the unused case. The quarterly language (Q3 at 2–3%, Q4 a mid-single-digit exit) only adds up to about the 3% bottom.

Weighting the stated path by seasonal sales — Q1 0.5% on $5,951 million, Q2 3.0% on $6,265 million, Q3 at the 2.5% midpoint on the $6,053 million base, and Q4 at 5% on $6,838 million — lands near 2.8% core for the year. Even a 3% Q3 and a 6% Q4 lands near 3.2%. A 4% year needs a Q4 core rate well through mid-single digits. Gugino told the street to anchor to the low end. That instruction was about the core range, not about EPS.

The EPS raise is real and smaller than it looks. The range moved from $8.35–$8.50 in January, to $8.35–$8.55 in April, to $8.45–$8.60 in July. Gugino put the early Masimo close at about $0.07–$0.08 and said the new range includes a second-half hedge for mix and currency. First-half adjusted EPS is $2.06 + $1.94 = $4.00, versus $3.68 in the first half of 2025. The $8.525 midpoint leaves about $4.53 for the second half, versus $4.12 last year. FMP's Q3 + Q4 sum is about $4.49. Q3 consensus of $1.91 is +1.1%. Q4 consensus of $2.58 versus $2.23 is +15.9%. The year the Street is modeling is not a Q3 earnings year.

FY revenue consensus of $26,342 million is +7.2% versus FY2025 sales of $24,568 million. Core midpoint 3.5% plus FY FX of about +0.5% is roughly +4% before acquisitions, or about $25.6 billion. The residual is Masimo, not a 300 bp bet against the core guide. FY2027 is not guided. FMP's $28,451 million and $9.30 are consensus only, about +8.0% and +9.3% versus the FY2026 averages, and a full year of Masimo against a 2026 stub is part of that step.

Q3 2026 has not printed. Guide columns are the July 21 supplement. Consensus exists only at consolidated revenue, EPS, and EBITDA. Segment rows have no FMP line. Internal is n/a on every row. Where both sides put a number on the same object, the only clean gap is FY adjusted EPS: Street −0.2% versus the $8.525 midpoint.

Current quarter — Q3 2026

The 2–3% headline is a respiratory math problem, not a new downturn in the ex-respiratory book. Q3 2025 was the odd quarter: respiratory helped core by about 50 bps on the company's bridge. Q3 2026 is guided to a 250 bp drag. Ex-respiratory has been stepping up, and the guide takes the next step. Gross margin is the reason a 26.5% bogey may be harder than the last one. The compression widened from −50 bps in Q3 2025 to −90 bps in Q1 2026 to −170 bps in Q2. The last time they printed 26.5% as the bogey they delivered 27.1%. History says 26.5% is a floor. The gross-margin trend says the beat is getting smaller.

Eight-quarter trajectory

Columns are quarters. YoY is versus the same quarter a year earlier, never the sequential quarter. Margin YoY rows are that compare, calculated from the cited levels in the row above. A dash means the year-ago level is not on this table. Q1 2025 company core was flat on the 8-K; Daloopa did not return that point. Q3 2025 sales YoY is the company rate, not the 10 bp-lower dollar calculation. Q3 2026 is not on this table.

Reported sales growth accelerated from +3.7% in Q1 to +5.5% in Q2, and core did the same, from 0.5% to 3.0%. Those are changes in the year-over-year rate, not a sequential dollar compare. Adjusted operating margin is not a straight slide into this print: Q4 2025 was already −140 bps versus Q4 2024, Q1 2026 was +60 bps, and Q2 was −20 bps. Gross-margin YoY has been negative on every quarter in this table that has a compare, and the decline widened from −50 bps in Q3 2025 to −170 bps in Q2 2026. The segment rates did not. Life Sciences is the acceleration, and derived segment margin expanded with it: Q2 adjusted operating profit of $395 million on $1,879 million of sales is about 21.0%, versus about 19.3% a year earlier on $343 million and $1,777 million, roughly +170 bps. Biotechnology margin stayed near 41% ($787 million on $1,920 million). The shipment delay did not crack that margin. Diagnostics adjusted profit was $605 million versus $602 million, about flat, while sales rose 6.8% because Masimo is in the reported dollar. Free cash flow was $1,265 million, +15.6% versus $1,094 million. Q3 free cash flow is not guided; the year-ago quarter was $1,370 million.

Five-year annual path

2021–2022 dollars are not a clean run-rate. COVID testing and the Veralto separation sit in that base. 2022 sales and adjusted EPS below are the restated continuing-operations amounts. The trajectory that matters is 2023 to 2025: core turned from a double-digit decline to +2%, and adjusted EPS troughed in 2024.

The sales and EPS YoY rows are blank (n/c) before 2025 because COVID testing and the Veralto separation make those bases a bad compare. The +2.9% and +4.3% are 2025 versus 2024 only. The 2026 sales YoY cell is FMP revenue versus that 2025 sales base, not a core rate. Core is still a low-single-digit recovery, not a return to the pre-2023 algorithm. Adjusted EPS is the line they are willing to raise. Full-year adjusted operating margin fell 40 bps in 2025, and there is no FY margin guide for 2026, only the Q3 point. StatLab, about $250 million of FY2025 revenue, is expected to close by year-end and is not in the 2026 revenue guide.

FQ+1 — Q4 2026

No revenue-dollar, EPS, or margin guide. The supplement's Q4 column is a mid-single-digit core exit, a flat respiratory impact, and about $500 million of respiratory revenue, in line with Q4 2025. The resin shipments are explicitly not assumed to come back in Q4. If they did, that would be upside to the plan, not the plan.

FY2026 guide still in force — FY2027 is not guided

This is the framework heading into the Q3 print, not a new guide. FY2027 has no company number.

Confidence is high on the mechanics and deliberately low on bioprocessing revenue timing. Respiratory is sized, not hoped: about $325 million versus about $500 million in Q3 2025, and Q2 respiratory came in on the $250 million they had teed up. The ex-respiratory book only has to inch from 4.5% to about 5%. Life Sciences at 3%–4% is +400 to +500 bps versus Q3 2025's −1.0%. Gugino said Pall project timing, not an end-market rollover, is why that guide is not higher. Gugino called Q2 the strongest Life Sciences quarter in several years and raised that segment versus prior expectations. China diagnostics is a fading headwind, not a growth engine: pricing has stabilized, and the VBP drag is supposed to be smaller in Q3 and Q4. Academia is less than 5% of revenue and is stable, not inflecting.

The resin pushout is the assumption that has to hold and the one they will not put back into the year. A few large commercial customers, chromatography resin, shipments planned for Q2 and Q3, delayed for production-schedule and site-readiness reasons. Gugino sized it at about $50–$60 million and roughly 500 bps of bioprocessing growth in Q2, and a little north of $100 million for the year, moved into 2027. "Some chance" of a Q4 return is not in the plan. Upstream consumables were strong double-digit, which is the evidence this is not a broad consumables recession. Customer inventories, on their process, are lower than the prior year, not higher. Orders in both consumables and equipment grew mid-teens. Those larger resin orders were already in backlog. Orders are not revenue, and the guide treats them that way.

The EPS raise is not an organic-earnings raise of the same size. About $0.07–$0.08 is Masimo closing in 2026 instead of at year-end. The 10-Q puts Masimo's 2025 revenue at about $1.5 billion. Q2's acquisition contribution was a stub, +1.5 points of the +5.5% sales increase. Q3 is the first full quarter, so reported growth should gap above core. H1 Masimo growth was described as high-single-digit. Cost synergies were outlined at about $125 million by year five and revenue synergies at about $50 million. None of that is a Q3 core driver. StatLab is still pending and does not belong in the Q3 model. Currency flips from a Q2 tailwind to a Q3 headwind of about −1%.

Tone across the last four calls went one direction on the portfolio and the other direction on the published range. October 2025 was a beat they refused to spend on a higher 2026 growth rate. January set 3–6% core and $8.35–$8.50, and Gugino said the EPS math assumed the low end, "think 3% to 4%." April held 3–6%, raised only the EPS ceiling, and cut respiratory to $1.6 billion–$1.7 billion. July cut the published core range to 3–4%, raised EPS again because Masimo closed early, and parked a hedge in the second half. Rhetorical confidence in orders, Life Sciences, and ex-respiratory growth stepped up. The formal growth range stepped down. From January to July the EPS floor went from $8.35 to $8.45 and the core ceiling went from 6% to 4%. That gap is the setup.

Nothing since July 21 has replaced the guide. The August 3 release naming Julie Sawyer Montgomery President and CEO effective October 1 says, in one sentence, that third-quarter and full-year 2026 guidance is unchanged. Blair steps down as CEO and director that day, stays a senior advisor through year-end, and a consultant through March 31, 2027. The September 15 dividend is the same $0.40. The September 22 notice only sets the call. There is no Danaher presentation on the IR events list at the September healthcare conferences. No respiratory, bioprocessing, China, or currency update. Daloopa's 2026Q3 document list was empty. The June 26 FX assumption has not been refreshed.

The risks they actually flagged, and that this print can confirm or break:

1. Another slip from the same handful of resin customers breaks the mid-single-digit bioprocessing frame. A Q4 shipment would make the guide light, and they said that is not the plan.
2. Respiratory can miss in either direction, and the margin moves with it. Gross margin is already 170 bps below Q2 2025.
3. A guided −140 bp margin decline can be read as the productivity story stalling even if ex-respiratory core is fine.
4. The EPS hedge is intentional. The floor moved up more than the ceiling. $8.60 is not the operating plan.
5. The Middle East was a limited first-half impact, not a zero. The Q2 10-Q discloses delays, higher logistics costs, and a live risk to energy costs and demand. The Q3 guide was not built with a disclosed Middle East revenue haircut.
6. Tariffs were not material through the first half. The new item is definitional: core sales will start excluding customer-returned tariff refunds in the Q3 10-Q.
7. The first call under a new CEO is a tone event even when the numbers were reaffirmed. Speakers were not named in the September 22 notice.

Guidance has not been withdrawn. The CFO has not changed. The growth range was narrowed, which is the pre-earnings pattern that matters. Full-year 2025 adjusted EPS finished at the high end of the final $7.70–$7.80 range, not through it. They walk the range up and then land on the top tick. An in-line Q3 against 2–3% core and 26.5% margin would be consistent with every sentence they have committed to. It would not confirm the acceleration story. That confirmation is a 5% ex-respiratory print and a Q4 exit that stays mid-single digit without another shipment excuse.

Consensus is underwriting a Masimo-driven revenue print and a barely-growing EPS print. It is not underwriting a bioprocessing snapback. The unresolved debate is whether mid-teens orders mean the developed-market resin delay is timing. Developed-market biotechnology dollars fell about 4% in Q2 (North America $583 million versus $612 million, Western Europe $689 million versus $708 million). High-growth biotechnology was $574 million versus $448 million, +28.1%. That geography fits a handful of large commercial deferrals better than a broad destock. Sartorius described the same shape on its first-half call — timing pushed into 2027, underlying consumables still growing — and its consumables were faster than Danaher's reported bioprocessing growth. The timing story is not Danaher-specific. Danaher is not currently the growth leader in the category, which is the share question the call will get.

Management has been repeating the order book. The street has chosen the shipment guide: full-year core narrowed to 3–4%, anchor at the low end, bioprocessing cut to mid-single digit, and FY EPS set at the midpoint of a range that was raised for a beat and an early close. That is the contradiction. It is only a contrarian setup if the order book converts. The track record says they hit earnings guides and have started to miss, or walk down, the growth phrase when respiratory or shipment timing blows a hole in the headline.

Two items are real and not in the $1.91. Beckman has a CE mark for Access p-Tau217 and does not have the U.S. clearances Roche and C2N took after the Q2 call. That is share of mind, not Q3 revenue. IDT and Aldevron launched research-grade Cas9 mRNA on September 16. It supports the Life Sciences narrative and does not move a $1.9 billion segment. StatLab remains a year-end close. A close before October 21 would be a surprise versus the language on the call. China product launches in September are commercial action inside the quarter. They do not change the flat Diagnostics guide.

Window is July 22 through September 24. Nothing in it revises Q3 core of 2–3%, FY core of 3–4%, or adjusted EPS of $8.45–$8.60. The operating debate is the same one left on July 21: bioprocessing shipment timing and the Cepheid respiratory headwind. The items that would move the setup — a StatLab close, a Cytiva shipment update, a China volume update, or a change to the respiratory assumption — did not appear.

Leadership is continuity, not a new algorithm: a diagnostics operator becomes CEO, Blair stays in the building through year-end, the bioprocessing EVP is retained with an equity award, and adjusted guidance is restated rather than reset. The governance blemish is the August 21 sale. The product tape is real and unquantified. Beckman also launched the DxU 1800 urinalysis system in the U.S. on July 23 and pushed a China menu in mid-September. Those support the Diagnostics share-gain record. They are not a reported order or a core-growth figure.

Consistent beater on adjusted EPS, with the beat getting smaller. Over the last 12 reported quarters Danaher beat FMP adjusted-EPS consensus 11 times, tied once (Q4 2024), and missed never. The last four quarters are 4/4. Revenue beat in 11 of 12 quarters and 3 of 4 recently. The only revenue miss is Q1 2026, $5,951 million versus a $5,982 million FMP estimate, −0.5%. What is deteriorating is the size of the beat. The four-quarter average EPS surprise stepped down from about +10.4% to +8.5% to +6.0%. The average revenue surprise stepped down from about +3.9% to +2.5% to +0.8%. Q2's +$0.09 on $1.94 versus $1.85 is the second-smallest positive EPS beat in the window. The business got better while the beat got smaller. That is consensus catching a recovery, not evidence the recovery reversed.

FMP scores the adjusted number. Q2 GAAP diluted EPS was $1.23 and adjusted EPS was $1.94. FMP's actual is $1.94. Q4 2023 revenue in the heatmap uses a Seeking Alpha-implied consensus of about $6,036 million, because FMP's revenue actual and estimate for that quarter are inconsistent with Daloopa sales of $6,405 million. The 11/12 revenue count does not depend on that correction. Q3 2026 is not on the grid.

Green is a beat, and the solid green cells are surprises of about 3% or more on revenue and about 8% or more on EPS. Yellow is the Q4 2024 EPS tie and the two narrow revenue beats that faded into noise. The single red cell is the Q1 2026 revenue miss. No EPS cell is red. Read left to right: the revenue row fades, breaks once, and only partly rebounds. The EPS row stays green, and the greens get lighter after Q3 2025.

The repeating mechanism is narrower than "Danaher always beats." Respiratory above the internal bogey produced the wide surprises (Q3 2023, Q4 2023, Q1 2025, Q3 2025). Q3 2025 is the clean version: core of 3.0% and a margin of 27.9% that ran about 240 bps above a ~25.5% bogey, so EPS beat by 9.9% on only a +0.9% revenue surprise. Respiratory in line or light, with productivity still ahead of the margin bogey, produces a modest EPS beat and a revenue result that can go either way. Q1 2026 is the template for this quarter: revenue missed, margin was 30.2% versus a ~28.5% expectation, and EPS still beat by 6.2%. Versus its own margin guide the recent strip is six beats and one narrow miss (Q4 2024, 31 bps under a 30% guide), and the last beat was only +60 bps.

Read-through for October 21. The EPS bar of $1.91 is only two cents above $1.89. Even the shrunken recent dollar beats would clear it, and the 26.5% bogey is 140 bps below last year's Q3 margin and 60 bps below the Q2 exit. A beat on adjusted EPS remains the base case. A beat on revenue is no longer automatic. The street's revenue number sits well above the core guide because of Masimo, so a historical 1–3% beat versus a core-like consensus is not the same test as clearing $6,554 million. Missing $1.91 would be new. Merely hitting it, with core at the low end of 2–3% and the margin on 26.5%, would mean the hedge was the forecast. The swing factor is whether the respiratory headwind stays inside the 250 bps they have already told the street to expect, and whether Life Sciences and the bioprocessing order book show up as revenue.